Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Gilead Sciences (GILD – Research Report), boosting the price target to $115.00.
Daina Graybosch’s rating is based on the promising commercial potential of Gilead Sciences’ Trodelvy following the successful results of the ASCENT-04 trial. This pivotal Phase 3 trial demonstrated that Trodelvy, when combined with pembrolizumab, significantly improved progression-free survival in patients with metastatic PD-L1+ triple-negative breast cancer. The success of this trial suggests that Trodelvy could become a new standard of care for these patients by mid-2026, potentially driving substantial revenue growth for Gilead in the oncology sector.
Additionally, the positive outcomes of ASCENT-04 enhance the likelihood of success in the ongoing ASCENT-03 trial, which targets a broader patient population with triple-negative breast cancer. The results also provide confidence in Gilead’s EVOKE-03 trial for non-small cell lung cancer, indicating that Trodelvy can effectively combine with pembrolizumab. Despite a muted market reaction, Graybosch anticipates that investor appreciation for Trodelvy’s success will increase as more data becomes available and macroeconomic uncertainties resolve.
Graybosch covers the Healthcare sector, focusing on stocks such as Merck & Company, BioNTech SE, and Gilead Sciences. According to TipRanks, Graybosch has an average return of -16.7% and a 29.94% success rate on recommended stocks.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $125.00 price target.